The definitive agreement will see the payment of up to $1bn to Exonics' equity holders if future development and regulatory milestones are met for certain programmes. Fate Therapeutics has raised a total of $1.2B in funding over 16 rounds. Will Boston Scientific Stock See Higher Levels? I, Fate Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($0.75) Per Share (NASDAQ:FATE), Q1 2023 EPS Estimates for Fate Therapeutics, Inc. (NASDAQ:FATE) Reduced by Analyst, Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript, Fate Therapeutics Full Year 2022 Earnings: Beats Expectations. Currency in USD Follow 2W 10W 9M 6.11 +0.02 (+0.33%) At close: 04:00PM EST 6.29 +0.18 (+2.95%) After hours: 05:58PM EST. This Starts a Race to the Bottom. You may opt-out by. It appears so. Dive Brief: Johnson & Johnson will pay Fate Therapeutics $100 million to co-develop a group of allogeneic, or "off-the-shelf" cell therapies for cancer. Per deal terms, J&J will buy $50 million Fate shares at $31 apiece, a roughly 47% premium to Fate's $21.07 closing price on Thursday. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Posted by Defense World Staff on Mar 4th, 2023. Investigator-assessed ORR was 11.4% in patients with NPCB, 16.9% with PCB, and 25.0% in CPI-nave. Should I buy or sell Fate Therapeutics stock right now? Lazard Asset Management LLC lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE Get Rating) by 27.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. It has seen positive findings from early trials for FT500, something that has kept the stock price buzzing of late. The outperformance of FATE can be attributed to positive findings from early clinical trials of FT500 and FT516 treatments. 40% of employees would recommend working at Fate Therapeutics to a friend and 22% have a positive outlook for the business. My No. What is a Good Dividend Yield? Five Day: FATE 16%, vs. S&P500 4%; Outperformed market, Ten Day: FATE 13%, vs. S&P500 1.8%; Outperformed market. The fund owned 153,051 shares of the biopharmaceutical company's stock after purchasing an additional 3,038 shares during the period. Following the sale, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. Given the current momentum in the stock, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is an 64% chance of a rise in FATE stock over the next month (twenty one trading days). The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Fate Therapeutics is registered under the ticker NASDAQ:FATE . Get daily stock ideas from top-performing Wall Street analysts. What is Fate Therapeutics' stock price today? Quantbot Technologies LP bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $69,000. If you wish to serve as lead plaintiff, you . It's an emerging field of research that's still in its early stages. Janssen agreed to pay Fate $50 million upfront, while another J&J entity, Johnson & Johnson Innovation-JJDC, will purchase newly-issued shares of Fate's common stock at a price per share of . Fate Therapeutics ( FATE) - Get Free Report stock tumbled Friday after the biopharma reported mixed results from a clinical trial of its treatment for B-cell lymphoma. publish chart | save to portfolio | create alert | compare perf. This rating has decreased by -28% over the last 12 months. baseball font with tail generator. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Several other research firms have also recently issued reports on FATE. Get Fate Therapeutics Inc (FATE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Fate Therapeutics will receive a $50 million upfront payment and a $50 million equity investment. Fate Therapeutics Market Cap Make that two consecutive days of riding the momentum from the Juno Therapeutics acquisition. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Fate Therapeutics by 17.1% during the 1st quarter. [4] Through the years, many have been acquired . Eli Lilly Slashed Insulin Prices. Fate has been focused on the oncology and immunology pipeline for multiple cancer types including myeloid leukemia, B-cell lymphoma, and multiple myeloma among others. Fate Therapeutics' stock was trading at $10.09 at the beginning of the year. Market Volatility To Continue Its The Economy (Stupid)! In the past three months, Fate Therapeutics insiders have bought 75.98% more of their company's stock than they have sold. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. The rise can largely be attributed to increased investor expectations from Fates pipeline, which focuses on a class of treatment that is based on Natural Killer cells. View our FATE earnings forecast. Moderna leans into oncology with CytomX deal worth up to $1.2B Fate ends potential $3B Janssen partnership. Most of the 18x rise of the last 3 years can be attributed to expansion of its P/S multiple, as the company does not have any marketable product yet. It is engaged in the development of programmed cellular immunotherapies for cancer and immune. The pact is the latest bet by a large drugmaker on allogeneic cell therapies, which could be cheaper to make and more convenient than the "autologous" CAR-T treatments that have won approval but struggled commercially. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $91,000. While we believe that FATE stock is richly valued, the market potential is huge, especially in multi-billion dollar - oncology treatments. Research & Science Based on 84 salaries Scientist 30 salaries Senior Research Associate 7 salaries View More Engineering Based on 11 salaries Manufacturing Associate II Insiders own 17.34% of the companys stock. Fate Therapeutics employees are showing high interest in Vehicle Inventory Acquisition , Attack Surface , and Eclipse IDE, according to Bombora. [Updated: 2/10/2021] Can The FATE Stock Rally Continue? More importantly, there is 60% probability of a positive return over the next twenty-one trading days and a 53% probability of a positive excess return after a -5% change over five trading days, based on historical data. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading days, and we believe the stock will likely continue to rally in the near term. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. View the best growth stocks for 2023 here. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. These companies have yet to prove off-the-shelf approaches can match, or surpass, what has been seen with CAR-T without triggering serious or potentially deadly immune reactions. According to the Trefis Machine Learning Engine, which identifies trends in a companys stock price using historical stock data, returns for FATE stock average around 6% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). 1985 - 2023 BioSpace.com. Jeereddi Investments LP Increases Position in Alphabet Inc. Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products. Twitter Is Just One Reason Why, Gamma Mama! It appears so. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. Get the free daily newsletter read by industry experts. Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. Twitter. Fate Therapeutics has a 52 week low of $4.02 and a 52 week high of $43.12. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Shares of FATE stock can be purchased through any online brokerage account. Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. UBS Group AG Reduces Stock Holdings in Builders FirstSource, Inc. (NYSE:BLDR), Boothbay Fund Management LLC Has $299,000 Stock Holdings in GMS Inc. (NYSE:GMS), Alphabet Inc. (NASDAQ:GOOG) Shares Bought by Capital Square LLC, Jeereddi Investments LP Increases Position in Alphabet Inc. (NASDAQ:GOOG), Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products (NYSE:SON), Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. (NYSE:GGG), MML Investors Services LLC Buys 3,360 Shares of Wolfspeed, Inc. (NYSE:WOLF), Boothbay Fund Management LLC Takes Position in Loews Co. (NYSE:L), Boothbay Fund Management LLC Sells 9,611 Shares of Portillos Inc. (NASDAQ:PTLO), MML Investors Services LLC Sells 139 Shares of Extra Space Storage Inc. (NYSE:EXR), Lazard Asset Management LLC Has $308,000 Stake in Marqeta, Inc. (NASDAQ:MQ), Lazard Asset Management LLC Has $329,000 Position in The Williams Companies, Inc. (NYSE:WMB), Boothbay Fund Management LLC Invests $267,000 in Synaptics Incorporated (NASDAQ:SYNA), 7,728 Shares in SEI Investments (NASDAQ:SEIC) Acquired by Ergoteles LLC, Lazard Asset Management LLC Trims Stake in iQIYI, Inc. (NASDAQ:IQ), 2,549 Shares in Hess Co. (NYSE:HES) Acquired by Boothbay Fund Management LLC, The Interpublic Group of Companies, Inc. (NYSE:IPG) Shares Sold by Lazard Asset Management LLC, Boothbay Fund Management LLC Acquires 38,651 Shares of Consolidated Communications Holdings, Inc. (NASDAQ:CNSL), Boothbay Fund Management LLC Takes $260,000 Position in Advanced Drainage Systems, Inc. (NYSE:WMS), Boothbay Fund Management LLC Takes $288,000 Position in ShotSpotter, Inc. (NASDAQ:SSTI). Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The revenues are expected to see a sharp jump of over 90% to $20.4 million in 2020, due to collaboration agreements with Janssen and Ono. Five Days: FATE 9.3%, vs. S&P500 0.7%; Outperformed market, (18% likelihood event; 49% probability of rise over next 5 days), Ten Days: FATE 7%, vs. S&P500 0.9%; Outperformed market, (31% likelihood event; 45% probability of rise over next 10 days), Twenty-One Days: FATE 3.6%, vs. S&P500 0.01%; Outperformed market, (43% likelihood event; 56% probability of rise over next 21 days). Shares of FATE stock opened at $6.01 on Tuesday. FATE - Fate Therapeutics, Inc. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. Its pretty powerful to test the trend for yourself for Fate Therapeutics stock by changing the inputs in the charts above. Using the recent trend (20% fall in a week) and seven years of historical stock data, the Trefis AI engine finds that the stock will likely move 15.1% over the next one month (twenty-one trading days), outperforming the broader indices. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. FT576. The 16% rise for FATE stock compares with 4% gains seen in the broader S&P 500 index. See Top Rated MarketRank Stocks Here The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Could 0DTE Options Be The Cause Of The Next Market Meltdown. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, MarketBeat.com's FREE daily email newsletter. FATE stock has rallied from $22 to $114, significantly outperforming the S&P which moved 70% over the same period, with the resumption of economic activities as lockdowns are gradually lifted and vaccines are being approved in multiple countries. MACHINE LEARNING ENGINE try it yourself: IF FATE stock moved by -5% over five trading days, THEN over the next twenty-one trading days, FATE stock moves an average of 6%, which implies an excess return of 4% compared to the S&P500. According to data from MarketBeat, Fate Therapeutics currently has a consensus rating of Hold and an average price target of $24.69. By Alex Keown. FATE Fate Therapeutics Inc 6,209 $6.11 $0.02 (0.33%) Today Market Cap $583.99M Volume (M) 1.52M 52-Wk High $43.12 52-Wk Low $4.02 About Feed Sentiment Fundamentals News There is no chart data available for this period 1d 1w 1m 3m 6m 1y All Sentiment Score Message Volume Score Disclaimer: This is informational only. The company's quarterly revenue was up 159.9% on a year-over-year basis. Fate Therapeutics, Inc. (NASDAQ: FATE) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Welcome to the Fate Therapeutics Fourth Quarter 2022 Financial Results Conference Call.. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks - although FATE stock appears to be an exception to this general observation. Case 1: Fate Therapeutics stock drops by -5% or more in a week, Case 2: Fate Therapeutics stock rises by 5% or more in a week. Fate Therapeutics has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise. UNLOCK PREMIUM DATA WITH DATABOOST Fate Therapeutics does not have a long track record of dividend growth. "From speaking to management, we think this is exactly the type of deal [Fate] was looking for," wrote Cantor Fitzgerald analyst Alethia Young, referring to a back-loaded agreement that gives the company the chance to keep some rights to the programs in the alliance. Large investors have recently added to or reduced their stakes in the company. In other Fate Therapeutics news, Director John Mendlein bought 88,048 shares of Fate Therapeutics stock in a transaction that occurred on Wednesday, January 11th. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass-produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment, the company said. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. The outperformance of FATE can be attributed to positive findings from early clinical trials of FT500 and FT516 treatments. Fate Therapeutics Stock Performance. Zscaler, Inc Plummets, Is It Time To Buy The Dip? Also, CEO J Scott Wolchko sold 45,907 shares of the stock in a transaction dated Tuesday, January 10th. Drug price reforms and regulatory scrutiny present challenges for large drugmakers, although successes in Alzheimers and obesity have brought new opportunities, too. Fates iPSC platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses, according to the company. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Answer: If you buy and hold Fate Therapeutics stock, the expectation is over time the near term fluctuations will cancel out, and the long-term positive trend will favor you - at least if the company is otherwise strong. According to analysts' consensus price target of $24.69, Fate Therapeutics has a forecasted upside of 304.1% from its current price of $6.11. Their FATE share price forecasts range from $7.00 to $90.00. Fate Therapeutics delivered mixed results for its lymphoma treatments, which caused Fate stock to crumble on Friday.. X. You can test the answer and many other combinations on the Trefis Machine Learning Engine to test Fate Therapeutics stock chances of a rise after a fall. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. But now that the stock has fallen 20% in just five days, will the FATE stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? The Axsome Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. Raymond James & Associates raised its stake in Fate Therapeutics by 42.6% during the first quarter. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. Powered by Madgex Job Board Software. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Mr. Beitel is responsible for developing and implementing strategic growth initiatives. To see all exchange delays and terms of use please see Barchart's disclaimer. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. Funding. March 1, 2023|markets.businessinsider.com, February 27, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com, February 13, 2023|markets.businessinsider.com. Last updated: Feb 26, 2023 Powered by IT Spend by Aberdeen This year, Fate Therapeutics is projected to spend $682.2K on IT, according to Aberdeen. 1 dividend stock for a LIFETIME of income. The companys approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Owens Corning (NYSE:OC) Shares Sold by Capital Fund Management S.A. Nucor Co. (NYSE:NUE) Shares Sold by Blueshift Asset Management LLC, Stratasys Ltd. (NASDAQ:SSYS) Stock Holdings Lifted by AlphaCrest Capital Management LLC, Blueshift Asset Management LLC Lowers Stock Position in Urban Outfitters, Inc. (NASDAQ:URBN). Fate is all of that. Fate Therapeutics has a 12 month low of $4.02 and a 12 month high of $43.12. One share of FATE stock can currently be purchased for approximately $6.11. Purchases New Holdings in Ball Co. (NYSE:BALL), Blueshift Asset Management LLC Sells 21,016 Shares of Dell Technologies Inc. (NYSE:DELL), Cary Street Partners Investment Advisory LLC Has $126,000 Stock Holdings in Yum China Holdings, Inc. (NYSE:YUMC). When is Fate Therapeutics' next earnings date? A high percentage of insider ownership can be a sign of company health. The official website for the company is www.fatetherapeutics.com. Fate Therapeutics' stock is owned by a variety of institutional and retail investors. The company is currently working on multiple programs, including FT516 for the treatment of acute myeloid leukemia and B-cell lymphoma, FT596 to treat B-cell lymphoma, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. | March 3, 2023 First-generation autologous CAR-T therapies involve genetically edited immune cells taken directly from patients in a lengthy, logistically challenging and costly procedure. Guggenheim cut shares of Fate Therapeutics from a buy rating to a neutral rating in a research note on Tuesday, January 3rd. Vertex Pharmaceuticals has signed a definitive agreement to acquire all outstanding shares of gene editing therapies developer Exonics Therapeutics for an upfront payment of $245m. Fate Therapeutics saw its shares in the red after-hours Thursday night as durability concerns cast a shadow over its latest blood cancer data drop. He said the collaboration combines Janssens deep domain expertise in oncology, along with their proprietary technologies for targeting and binding certain tumors with Fates iPSC product platform to develop novel off-the-shelf CAR NK and T-cell cancer immunotherapies. Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Lazard Asset Management LLC Benzinga 4 days ago FATE SHAREHOLDER NOTICE: Hagens Berman, National Trial Attorneys, Encourages Fate. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Is UnitedHealth Stock A Better Pick Over This Healthcare Facility Company? The firms 50 day moving average is $6.77 and its 200 day moving average is $16.67. In-depth profiles and analysis for 20,000 public companies. Fate Therapeutics became the first entity to dose a patient with an engineered stem cell-derived cellular medicine in October, began enrolling a higher-dose cohort for a separate drug. BOSTON, MA / ACCESSWIRE / February 28, 2023 / Block & Leviton announces that a class action lawsuit has been filed against Fate Therapeutics, Inc. (NASDAQ:FATE) for securities law violations. Shares of the San Diego . FATE stock is also up a massive 18x from levels of $6 seen in early 2018, three years ago. Shares of FATE opened at $6.01 on Tuesday. Topics covered: startup launches, funding, IPOs and much more. Zscaler, Inc Plummets, Is It Time To Buy The Dip? In the last 90 days, insiders have sold 75,708 shares of company stock valued at $396,710. See our analysis on Fate Therapeutics Stock Chances of Rise for more details. Segall Bryant & Hamill LLC lifted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Rating) by 2.0% in the third quarter, Holdings Channel.com reports. In comparison, the S&P 500 has an average return of 3.1% over the next 21 trading days under Case 1, and an average return of just 0.5% for Case 2 as detailed in our dashboard that details the average return for the S&P 500 after a fall or rise. During the same quarter in the prior year, the firm posted ($0.72) EPS. Fate Therapeutics, Inc. has a 1 year low of $4.02 and a 1 year high of $43.12. See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams |Product, R&D, and Marketing Teams, This is a BETA experience. Now that FATE stock has seen a rise of 9% in five trading days, can it continue its upward trajectory, or is a decline imminent? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The San Diego biotech is getting $100 million to produce up to four new therapies that J&J will have the option to license, while J&J covers the associated R&D costs. Following the acquisition, the director now owns 246,139 shares in the company, valued at $1,395,608.13. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. And it couldnt be more wrong! Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $599.76 million and generates $96.30 million in revenue each year. Fate has been focused on the oncology and immunology pipeline for multiple cancer types including myeloid leukemia, B-cell lymphoma, and multiple myeloma among others. As analyst firm Jefferies noted in March, Precision,AllogeneTherapeutics and CRISPRTherapeutics, which each use different off-the-shelf approaches, could all produce notable human data this year. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. [Updated: 1/20/2021] Is FATE Stock Overbought? On corrections down, there will be some support from the lines at $63.99 and $66.95. The biotech shared an interim peek of data. Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. contact@marketbeat.com And the recent stock price growth means that some of the positives are already priced in at the current price of $114. Shares have lost about 21% in that time frame, underperforming the S&P 500. Since then, FATE stock has decreased by 39.4% and is now trading at $6.11. Out of 352 instances in the last eight years that Fate Therapeutics stock saw a five-day rise of 9% or more, 178 of them resulted in FATE stock rising over the subsequent one month period (twenty-one trading days). The rise can largely be attributed to increased investor expectations from Fates pipeline, which focuses on a class of treatment that is based on Natural Killer cells. The partnership will leverage San Diego-based Fate Therapeutics induced pluripotent stem cell (iPSC) product platform and Janssens proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates that will be developed against up to four tumor-associated antigens for hematologic malignancies and solid tumors. The company is currently working on multiple programs, including FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. More importantly, there is 60% probability of a positive return over the next twenty-one trading days and a 53% probability of a positive excess return after a -5% change over five trading days, based on historical data. Most of the 18x rise of the last 3 years can be attributed to expansion of its P/S multiple, as the company does not have any marketable product yet. The biopharmaceutical company earned $44.36 million during the quarter, compared to analyst estimates of $18.41 million. [Updated: 3/31/2021] Can FATE Stock Rebound? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Lazard Asset Management LLC Raises Stake in CDW Co. (NASDAQ:CDW), Verition Fund Management LLC Raises Stock Position in Teradyne, Inc. (NASDAQ:TER), Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE). Looking at the recent rally, the 9% rise for FATE stock over the last five days compares with a 0.7% growth seen in the broader S&P 500 index. Topics covered: Gene replacement therapy, gene editing, engineered cell therapy, manufacturing, pricing, reimbursement and much more. Several other hedge funds have also made changes to their positions in FATE. Alphabet Inc. Shares Bought by Capital Square LLC. FATE stock fares better after Case 1, with an average return of 6% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 3.8% for Case 2.